Study S000454

Safety, Tolerability and Pharmacokinetics Study of Multiple Rising Subcutaneous Doses of Survodutide in Chinese Participants With Overweight or Obesity (BMI 24.0 to 40.0 kg/m2) (Non-randomization, Open Label, Parallel Group Design)

ClinicalTrials.gov record

Registration

Registration: NCT06492135
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 30
Start: 2024-08-12
Primary completion: 2025-04-15
Lead sponsor: Boehringer Ingelheim
Conditions: Overweight; Obesity
Interventions: DRUG:survodutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

AUC0-168 (area under the concentration-time curve of survodutide in plasma over the time interval from 0 to 168h) [up to 7 days]
Cmax (maximum measured concentration of survodutide in plasma) after the first dose [up to 7 days]
Cmax (maximum measured concentration of survodutide in plasma) after multiple doses [up to 7 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.